OPRX OptimizeRx Corp

OptimizeRx Continues COVID-19 Webinar Series, Addressing the Rapid Adoption of Telehealth

OptimizeRx Continues COVID-19 Webinar Series, Addressing the Rapid Adoption of Telehealth

ROCHESTER, Mich., April 16, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, will continue its webinar series on COVID-19 next week to address the rapid adoption of telehealth with industry veterans from  and .

This will be the sixth in a series of OptimizeRx has been hosting to facilitate industry collaboration across healthcare verticals in response to COVID-19. The conversation around telehealth brings together thought leaders with deep industry relationships who have driven innovation in the healthcare space through the implementation of disruptive technologies and strategic collaboration.  

The panel will be moderated by OptimizeRx president, . She will be joined by , CEO of Carla Smith Health. Smith recently spearheaded American Telemedicine Association’s , a resource for providers looking to quickly establish telehealth services during a public health crisis. Smith previously served as EVP of HIMSS for 17 years, leading U.S. and Canada strategy. She was named one of the Most Powerful Women Thought Leaders in Health IT and Most Influential Woman in Health IT several years in a row by Health Data Management.

The panel will also include , founder & CEO of , who has 30 years of experience starting and building successful, disruptive, consumer-focused companies including .

Topic: Learning TogetherThe Rapid Adoption of Telehealth During COVID-19. Will it Stick? In the face of social distancing to prevent further spread of the coronavirus, telehealth has emerged as the safest and most viable way to ensure patients have access to medical consults and care.

While telehealth is not new, it is suddenly experiencing unprecedented demand and easing of regulations because of the coronavirus crisis. Will this lead to a more permanent use of telehealth? Will broader telehealth initiatives persist after the pandemic subsides? The discussion will address the intricacies and opportunities of this extraordinary moment for telehealth, the growing importance of virtual care and its place in telehealth, and what these changes mean for the healthcare industry as a whole.

Date: Wednesday, April 22

Time: 1:00 p.m. ET

The webinar is open and free to anyone interested in participating in a practical conversation with industry leaders. OptimizeRx hosts these discussions to explore the transformational changes occurring in healthcare, and to connect the various stakeholders in a way that drives innovation, collaboration and education. 

Register today at .

For more information about OptimizeRx’s webinar sessions, contact media relations at (754) 245-7070 or .

About OptimizeRx

OptimizeRx® (NASDAQ: OPRX), a digital health company, connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. As the nation’s largest digital platform connecting life sciences to the point-of-care, OptimizeRx provides a direct channel for pharma companies, payers, medtech, and medical associations to communicate with healthcare providers right within their workflow and also directly to patients.

The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform.

For more information, follow the company on , or visit .

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

OptimizeRx Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

Media Relations Contact

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

Investor Relations Contact

Ron Both, CMA

Tel (949) 432-7557

EN
16/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates F...

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technolo...

 PRESS RELEASE

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025...

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will...

 PRESS RELEASE

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Direct...

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, after serving as the interim...

 PRESS RELEASE

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth ...

 PRESS RELEASE

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fi...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HC...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch